We also examined whether patients with more than one ESR1 mutation (Fig. 3a) or a higher than median AF (Fig. 3b) showed differential outcome in the fulvestrant control arm, based on previous reports suggesting higher AFs of BRAF V600E mutations are associated with higher disease burden and shorter PFS to BRAF-targeted therapy23. The gene discussed is ESR1; the disease is atrial fibrillation.